Abstract: Metaplastic breast carcinoma (MBC) is a rare malignant breast tumor, and no effective chemotherapy unique to metaplastic carcinoma exists. As MBC is typically “triple negative”, endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in a poor prognosis. Anlotinib is currently being tested in patients with breast or cancer. Here, we report a successful case in which anlotinib was used to treat MBC. A 54-year-old female patient visited the hospital after the discovery of a left breast tumor 10 months prior, and tumor redness and swelling had lasted for more than one month. After admission, relevant examinations were performed. After left breast tumor puncture revealed left emulsified biological cancer, the tumor significantly increased in size, and bleeding was obvious after 2 cycles of the “EC” chemotherapy regimen. The curative effect was evaluated as progressive disease (PD). After two cycles of chemotherapy with the “PCb” regimen, the efficacy was still PD. The Karnofsky performance status (KPS) score of the patient after 4 cycles of chemotherapy was 60 points, with severe anemia, and she could not tolerate chemotherapy. The patient was given radiotherapy to stop bleeding, and the tumor further increased in size during radiotherapy. The curative effect was evaluated as PD. After a multidisciplinary consultation in our hospital, we initiated oral anlotinib (12 mg; 2 weeks on, 1 week off). The tumor significantly decreased in size after taking anlotinib, and the efficacy was evaluated as PR. Adverse reactions during treatment were controlled, and progression-free survival (PFS) reached up to 25+ months. The follow-up is ongoing. The patient has provided written informed consent for the case details and images to be published, and at the same time institutional approval was required to publish the case details, we report this case.

Keywords: breast metaplastic carcinoma, anlotinib, targeted therapy


中文翻译：

---

安罗替尼靶向治疗晚期乳腺化生癌病例报告

摘要：化生性乳腺癌（MBC）是一种罕见的恶性乳腺肿瘤，尚无化生性癌特有的有效化疗方法。由于 MBC 通常是“三阴性”，因此针对 Her2 的内分泌治疗和分子治疗可能不利，导致预后不良。安罗替尼目前正在乳腺癌或癌症患者中进行测试。在这里，我们报告了一个使用安罗替尼治疗 MBC 的成功案例。一名54岁女性患者，10个月前发现左侧乳腺肿瘤后来院就诊，肿瘤红肿持续一个多月。入院后进行了相关检查。左侧乳腺肿瘤穿刺显示左侧乳化生物癌后，肿瘤体积明显增大，“EC”化疗方案2个周期后出血明显。疗效评价为疾病进展（PD）。“PCb”方案化疗2个周期后，疗效仍为PD。患者化疗4个周期后Karnofsky体力状态（KPS）评分60分，严重贫血，不能耐受化疗。患者接受放疗止血，放疗期间肿瘤进一步增大。疗效评价为PD。在我院进行多学科会诊后，我们开始口服安罗替尼（12 mg；服用 2 周，停药 1 周）。服用安罗替尼后肿瘤明显缩小，疗效评价为PR。治疗期间不良反应得到控制，无进展生存期 (PFS) 达到 25 个月以上。后续行动正在进行中。患者已提供书面知情同意书，公开病例详情和图像，同时需要机构批准才能公开病例详情，我们报告此病例。

关键词：乳腺癌，安罗替尼，靶向治疗